A lack of family history may indicate that the condition was acquired.It is suggested that the dental/medical professional establish if the condition is a syndrome of another inherited condition such as:

Osteogenesis imperfecta - indicates Type I Dentinogenesis Imperfecta (see Shields Classification in Classification section)
Ehlers Danlos syndrome
Goldblatt syndrome
Schimke immune-osseus dysplasia
Brachio-skeleto-genital syndrome
Osteodysplastic and primordial short stature with severe microdontia
Opalescent teeth
Rootless molars[This is not a comprehensive list]
It can be useful to enquire about symptoms of osteogenesis imperfecta, as Type I Dentinogenesis Imperfecta (Shields Classification) is associated with osteogenesis imperfecta. Notable information includes:

History of bone fracture caused by minimal trauma
Short stature
Blue sclera
Hearing lossCommon dental features of osteogenesis imperfecta include:

Hypodontia
Oligodontia
Taurodontism
Unerupted permanent 2nd molars, with no obstruction in the path of eruption
Retrognathic maxilla

Differential diagnosis
Hypocalcified forms of amelogenesis imperfecta
Congenital erythropoietic porphyria
Conditions that can cause early loss of teeth e.g. Kostmanns disease, cyclic neutropenia, Chediak-Hegashi syndrome, histiocytosis X, Papillon-Lefevre syndrome
Permanent tooth discolouration caused by medications such as tetracyclines, or medical conditions such as rickets

Treatment
Preventive and restorative care are important as well as esthetics as a consideration. This ensures preservation of the patients vertical face height between their upper and lower teeth when they bite together. The basis of treatment is standard throughout the different types of DI where prevention, preservation of occlusal face height, maintenance of function, and aesthetic needs are priority. Preventive efforts can limit pathology occurring within the pulp, which may render future endodontic procedures less challenging, with better outcomes.
It is the first topical janus kinase inhibitor approved in the United States.In July 2022, ruxolitinib cream (sold under the brand name Opzelura) was approved for medical use in the United States for the treatment of vitiligo. Society and culture
Legal status
In November 2011, ruxolitinib was approved by the U.S. Food and Drug Administration (FDA) for the treatment of intermediate or high-risk myelofibrosis based on results of the COMFORT-I and COMFORT-II Trials.In 2014, it was approved in polycythemia vera (PCV) when there has been an inadequate response to or intolerance of hydroxyurea, based on the RESPONSE trial. Research
It is being investigated for plaque psoriasis, alopecia areata, relapsed diffuse large B-cell lymphoma, and peripheral T-cell lymphoma.In February 2016, a phase III trial for pancreatic cancer was terminated due to insufficient efficacy.Eight weeks-treatment with ruxolitinib blunted senescent cell-mediated inhibition of adipogenesis and increased insulin sensitivity in 22-month-old mice.As of September 2019, a clinical trial is in progress to evaluate "Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors". References
External links
"Ruxolitinib". Drug Information Portal. U.S. National Library of Medicine. "Ruxolitinib phosphate". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT03112603 for "A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs.